| Core follow-up availability | |
| variable | n_non_missing |
|---|---|
| ls_b | 37 |
| ls_1m | 30 |
| ls_12m | 32 |
| vexus_b | 37 |
| vexus_1m | 30 |
| vexus_12m | 31 |
| nyha_b | 37 |
| nyha_1m | 36 |
| nyha_12m | 33 |
Liver stiffness and T-TEER: cuaderno de análisis
versión 22 junio 2026
1 Importación de los datos
1.1 Disponibilidad de seguimiento
2 Tablas
Tablas exploratorias por categoría de LS, con contraste categórico y asociación con LS continua.
2.1 Variables clínicas por LS
| Clinical variables by liver stiffness | ||||||||||
| LS groups: LS≤6 kPa, 6<LS≤10 kPa, LS≥10 kPa. The continuous LS association is shown after Overall. | ||||||||||
| Variable | Overall | LS continuous association1 |
Group comparison by LS category
|
p (LS) | Group test2 | Assumption tests | Assumption results | |||
|---|---|---|---|---|---|---|---|---|---|---|
| LS≤6 kPa | 6 < LS ≤ 10 kPa | LS ≥ 10 kPa | p value | |||||||
| Clinical: Baseline — Overall n=37 | group ns: 10/18/9 | ||||||||||
| Age (years) | 77 (74-81) | Spearman rho=-0.08; p=0.636 | 78 (76-81) | 76 (71-81) | 75 (74-82) | 0.875 | 0.636 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.945 |
| Female (nº, %) | 22 (59%) | Wilcoxon rank-sum median delta=0.78 kPa; p=0.938 | 6 (60%) | 12 (67%) | 4 (44%) | 0.622 | 0.938 | Fisher exact | Expected counts | min expected=3.65 (<5) |
| Hypertension (nº, %) | 22 (59%) | Wilcoxon rank-sum median delta=-1.13 kPa; p=0.516 | 7 (70%) | 9 (50%) | 6 (67%) | 0.570 | 0.516 | Fisher exact | Expected counts | min expected=3.65 (<5) |
| Hyperlipidaemia (nº, %) | 13 (35%) | Wilcoxon rank-sum median delta=2.45 kPa; p=0.445 | 3 (30%) | 5 (28%) | 5 (56%) | 0.360 | 0.445 | Fisher exact | Expected counts | min expected=3.16 (<5) |
| Diabetes mellitus (nº, %) | 8 (22%) | Wilcoxon rank-sum median delta=-0.50 kPa; p=0.810 | 3 (30%) | 3 (17%) | 2 (22%) | 0.872 | 0.810 | Fisher exact | Expected counts | min expected=1.95 (<5) |
| Atrial fibrillation (nº, %) | 34 (92%) | Wilcoxon rank-sum median delta=-1.23 kPa; p=0.759 | 9 (90%) | 16 (89%) | 9 (100%) | 0.792 | 0.759 | Fisher exact | Expected counts | min expected=0.73 (<5) |
| Ischemic cardiomyopathy (nº, %) | 6 (16%) | Wilcoxon rank-sum median delta=0.02 kPa; p=0.757 | 2 (20%) | 2 (11%) | 2 (22%) | 0.613 | 0.757 | Fisher exact | Expected counts | min expected=1.46 (<5) |
| Aortic valve surgery (nº, %) | 7 (19%) | Wilcoxon rank-sum median delta=2.83 kPa; p=0.771 | 2 (20%) | 2 (11%) | 3 (33%) | 0.353 | 0.771 | Fisher exact | Expected counts | min expected=1.70 (<5) |
| TAVR (nº, %) | 3 (8%) | Wilcoxon rank-sum median delta=4.33 kPa; p=0.210 | 0 (0%) | 1 (6%) | 2 (22%) | 0.208 | 0.210 | Fisher exact | Expected counts | min expected=0.73 (<5) |
| Mitral valve surgery (nº, %) | 13 (35%) | Wilcoxon rank-sum median delta=1.13 kPa; p=0.987 | 5 (50%) | 5 (28%) | 3 (33%) | 0.555 | 0.987 | Fisher exact | Expected counts | min expected=3.16 (<5) |
| Chronic Kidney Disease (nº, %) | 16 (43%) | Wilcoxon rank-sum median delta=-0.17 kPa; p=0.878 | 4 (40%) | 8 (44%) | 4 (44%) | 1.000 | 0.878 | Fisher exact | Expected counts | min expected=3.89 (<5) |
| Number of diuretics | 1.6 (± 0.8) | Spearman rho=-0.03; p=0.882 | 1.7 (± 0.7) | 1.4 (± 0.8) | 1.8 (± 0.8) | 0.386 | 0.882 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.084; Levene p=0.802 |
| NYHA ≥3 (nº, %) | 24 (65%) | Wilcoxon rank-sum median delta=-1.25 kPa; p=0.656 | 7 (70%) | 12 (67%) | 5 (56%) | 0.818 | 0.656 | Fisher exact | Expected counts | min expected=3.16 (<5) |
| Edema (nº, %) | 21 (57%) | Wilcoxon rank-sum median delta=0.17 kPa; p=0.668 | 5 (50%) | 10 (56%) | 6 (67%) | 0.832 | 0.668 | Fisher exact | Expected counts | min expected=3.89 (<5) |
| Ascitis (nº, %) | 10 (27%) | Wilcoxon rank-sum median delta=0.00 kPa; p=0.824 | 3 (30%) | 4 (22%) | 3 (33%) | 0.801 | 0.824 | Fisher exact | Expected counts | min expected=2.43 (<5) |
| Diuretic resistance (nº, %) | 10 (43%) | t-test delta=0.14 kPa [-2.86, 2.58]; p=0.917 | 3 (60%) | 4 (33%) | 3 (50%) | 0.637 | 0.917 | Fisher exact | Expected counts | min expected=2.17 (<5) |
| MELD-XI | 13.1 (± 3.8) | Spearman rho=-0.05; p=0.769 | 12.2 (± 2.7) | 13.8 (± 4.4) | 12.9 (± 3.5) | 0.697 | 0.769 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.003; Levene p=0.661 |
| FIB-4 score | 2.7 (± 1.3) | Spearman rho=-0.02; p=0.889 | 3.0 (± 1.9) | 2.5 (± 1.1) | 2.8 (± 1.0) | 0.568 | 0.889 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.006; Levene p=0.465 |
| VEXUS ≥2 (nº, %) | 23 (62%) | t-test delta=1.97 kPa [-3.90, -0.03]; p=0.046 | 3 (30%) | 13 (72%) | 7 (78%) | 0.058 | 0.046 | Fisher exact | Expected counts | min expected=3.41 (<5) |
| Clinical: 1 month — Overall n=30 | group ns: 16/12/2 | ||||||||||
| Age (years) | 77 (74-81) | Spearman rho=-0.42; p=0.020 | 80 (76-83) | 76 (69-80) | 61 (54-68) | 0.080 | 0.020 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.524; Levene p=0.030 |
| Female (nº, %) | 22 (59%) | t-test delta=0.81 kPa [-2.35, 0.72]; p=0.288 | 9 (56%) | 6 (50%) | 2 (100%) | 0.619 | 0.288 | Fisher exact | Expected counts | min expected=0.87 (<5) |
| Hypertension (nº, %) | 22 (59%) | t-test delta=-0.13 kPa [-1.44, 1.70]; p=0.865 | 9 (56%) | 7 (58%) | 1 (50%) | 1.000 | 0.865 | Fisher exact | Expected counts | min expected=0.87 (<5) |
| Hyperlipidaemia (nº, %) | 13 (35%) | t-test delta=0.22 kPa [-1.83, 1.40]; p=0.786 | 5 (31%) | 5 (42%) | 1 (50%) | 0.855 | 0.786 | Fisher exact | Expected counts | min expected=0.73 (<5) |
| Diabetes mellitus (nº, %) | 8 (22%) | t-test delta=-0.18 kPa [-1.76, 2.12]; p=0.849 | 4 (25%) | 1 (8%) | 1 (50%) | 0.188 | 0.849 | Fisher exact | Expected counts | min expected=0.40 (<5) |
| Atrial fibrillation (nº, %) | 34 (92%) | t-test delta=-1.29 kPa [-1.79, 4.37]; p=0.397 | 16 (100%) | 10 (83%) | 2 (100%) | 0.283 | 0.397 | Fisher exact | Expected counts | min expected=0.13 (<5) |
| Ischemic cardiomyopathy (nº, %) | 6 (16%) | t-test delta=1.54 kPa [-4.06, 0.98]; p=0.221 | 0 (0%) | 3 (25%) | 0 (0%) | 0.094 | 0.221 | Fisher exact | Expected counts | min expected=0.20 (<5) |
| Aortic valve surgery (nº, %) | 7 (19%) | t-test delta=0.30 kPa [-2.24, 1.64]; p=0.756 | 3 (19%) | 2 (17%) | 1 (50%) | 0.590 | 0.756 | Fisher exact | Expected counts | min expected=0.40 (<5) |
| TAVR (nº, %) | 3 (8%) | Wilcoxon rank-sum median delta=-1.20 kPa; p=0.533 | 2 (12%) | 0 (0%) | 0 (0%) | 0.559 | 0.533 | Fisher exact | Expected counts | min expected=0.13 (<5) |
| Mitral valve surgery (nº, %) | 13 (35%) | t-test delta=-0.09 kPa [-1.53, 1.70]; p=0.914 | 7 (44%) | 3 (25%) | 1 (50%) | 0.508 | 0.914 | Fisher exact | Expected counts | min expected=0.73 (<5) |
| Chronic Kidney Disease (nº, %) | 16 (43%) | t-test delta=-0.31 kPa [-1.24, 1.87]; p=0.683 | 6 (38%) | 8 (67%) | 0 (0%) | 0.156 | 0.683 | Fisher exact | Expected counts | min expected=0.93 (<5) |
| Number of diuretics | 1.6 (± 0.8) | Spearman rho=0.27; p=0.149 | 1.3 (± 0.7) | 1.6 (± 0.8) | 2.0 (± 0.0) | 0.365 | 0.149 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.077; Levene p=0.477 |
| NYHA ≥3 (nº, %) | 2 (6%) | t-test delta=1.61 kPa [-5.89, 2.68]; p=0.449 | 0 (0%) | 1 (8%) | 0 (0%) | 0.467 | 0.449 | Fisher exact | Expected counts | min expected=0.07 (<5) |
| Edema (nº, %) | 7 (19%) | t-test delta=0.88 kPa [-2.79, 1.03]; p=0.354 | 2 (12%) | 4 (33%) | 0 (0%) | 0.466 | 0.354 | Fisher exact | Expected counts | min expected=0.40 (<5) |
| Diuretic resistance (nº, %) | 10 (43%) | t-test delta=0.78 kPa [-2.97, 1.40]; p=0.455 | 1 (17%) | 4 (44%) | 1 (50%) | 0.508 | 0.455 | Fisher exact | Expected counts | min expected=0.71 (<5) |
| MELD-XI | 12.6 (± 3.7) | Spearman rho=0.21; p=0.256 | 11.7 (± 2.7) | 14.1 (± 4.9) | 11.3 (± 1.8) | 0.283 | 0.256 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.004; Levene p=0.358 |
| FIB-4 score | 2.7 (± 1.1) | Spearman rho=0.02; p=0.917 | 2.7 (± 1.2) | 2.6 (± 1.1) | 2.4 (± 0.4) | 0.902 | 0.917 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.009; Levene p=0.641 |
| VEXUS ≥2 (nº, %) | 11 (37%) | t-test delta=0.40 kPa [-2.01, 1.20]; p=0.612 | 5 (31%) | 6 (50%) | 0 (0%) | 0.416 | 0.612 | Fisher exact | Expected counts | min expected=0.73 (<5) |
| Clinical: 12 months — Overall n=32 | group ns: 16/15/1 | ||||||||||
| Age (years) | 77 (74-81) | Spearman rho=-0.23; p=0.208 | 78 (73-82) | 76 (72-78) | 77 (77-77) | 0.662 | 0.208 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.002; Levene p=0.692 |
| Female (nº, %) | 22 (59%) | t-test delta=-0.15 kPa [-1.33, 1.63]; p=0.836 | 9 (56%) | 9 (60%) | 0 (0%) | 0.707 | 0.836 | Fisher exact | Expected counts | min expected=0.44 (<5) |
| Hypertension (nº, %) | 22 (59%) | t-test delta=-0.05 kPa [-1.43, 1.53]; p=0.946 | 10 (62%) | 7 (47%) | 1 (100%) | 0.586 | 0.946 | Fisher exact | Expected counts | min expected=0.44 (<5) |
| Hyperlipidaemia (nº, %) | 13 (35%) | t-test delta=0.34 kPa [-1.88, 1.20]; p=0.653 | 6 (38%) | 5 (33%) | 0 (0%) | 1.000 | 0.653 | Fisher exact | Expected counts | min expected=0.34 (<5) |
| Diabetes mellitus (nº, %) | 8 (22%) | t-test delta=0.42 kPa [-2.10, 1.27]; p=0.618 | 3 (19%) | 5 (33%) | 0 (0%) | 0.575 | 0.618 | Fisher exact | Expected counts | min expected=0.25 (<5) |
| Atrial fibrillation (nº, %) | 34 (92%) | t-test delta=-1.22 kPa [-1.77, 4.21]; p=0.412 | 16 (100%) | 13 (87%) | 1 (100%) | 0.274 | 0.412 | Fisher exact | Expected counts | min expected=0.06 (<5) |
| Ischemic cardiomyopathy (nº, %) | 6 (16%) | t-test delta=-1.01 kPa [-1.17, 3.19]; p=0.353 | 3 (19%) | 1 (7%) | 0 (0%) | 0.650 | 0.353 | Fisher exact | Expected counts | min expected=0.12 (<5) |
| Aortic valve surgery (nº, %) | 7 (19%) | t-test delta=0.14 kPa [-1.91, 1.63]; p=0.875 | 3 (19%) | 4 (27%) | 0 (0%) | 0.754 | 0.875 | Fisher exact | Expected counts | min expected=0.22 (<5) |
| TAVR (nº, %) | 3 (8%) | t-test delta=3.89 kPa [-5.94, -1.84]; p=<0.001 | 0 (0%) | 2 (13%) | 1 (100%) | 0.021 | <0.001 | Fisher exact | Expected counts | min expected=0.09 (<5) |
| Mitral valve surgery (nº, %) | 13 (35%) | t-test delta=-0.20 kPa [-1.31, 1.71]; p=0.791 | 6 (38%) | 6 (40%) | 0 (0%) | 1.000 | 0.791 | Fisher exact | Expected counts | min expected=0.38 (<5) |
| Chronic Kidney Disease (nº, %) | 16 (43%) | t-test delta=-1.05 kPa [-0.39, 2.49]; p=0.147 | 8 (50%) | 5 (33%) | 0 (0%) | 0.571 | 0.147 | Fisher exact | Expected counts | min expected=0.41 (<5) |
| Number of diuretics | 1.6 (± 0.8) | Spearman rho=0.22; p=0.223 | 1.4 (± 0.7) | 1.6 (± 0.7) | 3.0 (± NA) | 0.182 | 0.223 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.013; Levene p=0.694 |
| NYHA ≥3 (nº, %) | 4 (12%) | t-test delta=0.65 kPa [-2.85, 1.55]; p=0.551 | 1 (6%) | 3 (20%) | 0 (0%) | 0.416 | 0.551 | Fisher exact | Expected counts | min expected=0.12 (<5) |
| Edema (nº, %) | 4 (12%) | t-test delta=-0.21 kPa [-2.01, 2.42]; p=0.850 | 2 (12%) | 2 (13%) | 0 (0%) | 1.000 | 0.850 | Fisher exact | Expected counts | min expected=0.12 (<5) |
| Ascitis (nº, %) | 1 (3%) | t-test delta=2.88 kPa [-6.95, 1.19]; p=0.159 | 0 (0%) | 1 (7%) | 0 (0%) | 0.500 | 0.159 | Fisher exact | Expected counts | min expected=0.03 (<5) |
| Diuretic resistance (nº, %) | 10 (43%) | t-test delta=0.46 kPa [-2.32, 1.40]; p=0.611 | 3 (33%) | 5 (42%) | 1 (100%) | 0.643 | 0.611 | Fisher exact | Expected counts | min expected=0.41 (<5) |
| MELD-XI | 12.9 (± 3.9) | Spearman rho=0.11; p=0.559 | 12.5 (± 4.5) | 13.4 (± 3.5) | 15.2 (± NA) | 0.411 | 0.559 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.674 |
| FIB-4 score | 2.6 (± 1.3) | Pearson r=-0.08 [-0.44, 0.31]; p=0.701 | 2.8 (± 1.4) | 2.3 (± 1.1) | 4.4 (± NA) | 0.196 | 0.701 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.226; Levene p=0.280 |
| VEXUS ≥2 (nº, %) | 6 (19%) | t-test delta=2.25 kPa [-3.90, -0.59]; p=0.009 | 1 (6%) | 4 (29%) | 1 (100%) | 0.045 | 0.009 | Fisher exact | Expected counts | min expected=0.19 (<5) |
| 1 Continuous association: Pearson if both variables pass Shapiro-Wilk; otherwise Spearman. Binary rows: t-test if residual normality and Levene are adequate; otherwise Wilcoxon rank-sum. | ||||||||||
| 2 Group comparison: continuous variables use ANOVA if residual normality and variance homogeneity hold; otherwise Kruskal-Wallis. Binary variables use chi-squared when expected counts are adequate; otherwise Fisher exact. | ||||||||||
2.1.1 Nota estadística
Contraste por grupos de LS (p value) y asociación con LS continua (p (LS)).
Resultados con p<0.05: TAVR (nº, %) [Clinical: 12 months]; VEXUS ≥2 (nº, %) [Clinical: 12 months].
2.2 Variables ecocardiográficas por LS
| Echocardiographic variables by liver stiffness | ||||||||||
| LS groups: LS≤6 kPa, 6<LS≤10 kPa, LS≥10 kPa. The continuous LS association is shown after Overall. | ||||||||||
| Variable | Overall | LS continuous association1 |
Group comparison by LS category
|
p (LS) | Group test2 | Assumption tests | Assumption results | |||
|---|---|---|---|---|---|---|---|---|---|---|
| LS≤6 kPa | 6 < LS ≤ 10 kPa | LS ≥ 10 kPa | p value | |||||||
| Echo: Baseline — Overall n=37 | group ns: 10/18/9 | ||||||||||
| LVEF (%) | 57.5 (± 8.2) | Spearman rho=-0.08; p=0.658 | 59.3 (± 9.2) | 57.6 (± 7.1) | 55.6 (± 9.6) | 0.633 | 0.658 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.581; Levene p=0.715 |
| Basal RV diameter (mm) | 47.2 (± 5.8) | Spearman rho=0.09; p=0.597 | 45.6 (± 5.0) | 48.2 (± 6.4) | 47.0 (± 5.7) | 0.548 | 0.597 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.780; Levene p=0.645 |
| Right atrium area (cm²) | 28.8 (± 7.6) | Spearman rho=0.15; p=0.376 | 24.1 (± 10.4) | 31.4 (± 6.3) | 28.9 (± 3.6) | 0.052 | 0.376 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.145; Levene p=0.241 |
| TAPSE (mm) | 18.2 (± 5.2) | Spearman rho=-0.14; p=0.419 | 18.0 (± 4.1) | 18.8 (± 6.4) | 17.3 (± 3.4) | 0.775 | 0.419 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.325; Levene p=0.296 |
| S' Wave (cm/s) | 10.7 (± 2.5) | Spearman rho=0.02; p=0.907 | 10.7 (± 2.3) | 10.7 (± 2.7) | 10.8 (± 2.9) | 0.993 | 0.907 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.984; Levene p=0.965 |
| FAC (%) | 38.2 (± 8.7) | Spearman rho=-0.24; p=0.152 | 39.3 (± 3.3) | 39.5 (± 9.0) | 34.2 (± 11.4) | 0.314 | 0.152 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.562; Levene p=0.021 |
| RV-FWLS (%) | 19.9 (± 4.6) | Spearman rho=-0.08; p=0.656 | 20.1 (± 3.7) | 19.8 (± 5.5) | 19.8 (± 4.2) | 0.985 | 0.656 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.163; Levene p=0.540 |
| PASP (mmHg) | 33.3 (± 10.1) | Spearman rho=0.05; p=0.794 | 33.6 (± 9.3) | 31.3 (± 10.3) | 36.1 (± 11.2) | 0.601 | 0.794 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.118; Levene p=0.762 |
| RV coupling (TAPSE/PASP) | 0.63 (± 0.26) | Spearman rho=-0.09; p=0.659 | 0.54 (± 0.13) | 0.76 (± 0.29) | 0.52 (± 0.22) | 0.065 | 0.659 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.986; Levene p=0.155 |
| TR vena contracta (mm) | 11.2 (± 3.4) | Spearman rho=0.15; p=0.390 | 10.7 (± 4.2) | 11.0 (± 3.0) | 12.2 (± 3.3) | 0.459 | 0.390 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.005; Levene p=0.897 |
| GAP (mm) | 6.9 (± 1.7) | Spearman rho=0.26; p=0.130 | 6.3 (± 1.5) | 6.9 (± 1.5) | 7.7 (± 2.1) | 0.245 | 0.130 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.591; Levene p=0.544 |
| TR massive/torrential (nº, %) | 12 (32%) | Wilcoxon rank-sum median delta=2.45 kPa; p=0.194 | 2 (20%) | 6 (33%) | 4 (44%) | 0.533 | 0.194 | Fisher exact | Expected counts | min expected=2.92 (<5) |
| IVC diameter (mm) | 23.0 (± 3.8) | Spearman rho=-0.02; p=0.920 | 23.5 (± 4.9) | 22.9 (± 3.8) | 22.9 (± 2.7) | 0.920 | 0.920 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.133; Levene p=0.310 |
| Echo: 1 month — Overall n=30 | group ns: 16/12/2 | ||||||||||
| Basal RV diameter (mm) | 45.1 (± 6.1) | Pearson r=0.23 [-0.14, 0.54]; p=0.225 | 43.6 (± 6.4) | 48.1 (± 4.4) | 45.5 (± 12.0) | 0.172 | 0.225 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.307; Levene p=0.068 |
| Right atrium area (cm²) | 27.9 (± 5.9) | Pearson r=-0.14 [-0.48, 0.24]; p=0.461 | 28.8 (± 5.6) | 29.2 (± 4.9) | 24.8 (± 1.4) | 0.553 | 0.461 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.736; Levene p=0.295 |
| TAPSE (mm) | 18.4 (± 3.8) | Pearson r=0.12 [-0.26, 0.46]; p=0.545 | 18.2 (± 3.4) | 20.0 (± 3.3) | 21.5 (± 6.4) | 0.281 | 0.545 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.436; Levene p=0.386 |
| S' Wave (cm/s) | 10.1 (± 2.4) | Pearson r=-0.04 [-0.39, 0.33]; p=0.852 | 10.1 (± 2.4) | 10.6 (± 2.1) | 10.9 (± 5.2) | 0.843 | 0.852 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.237; Levene p=0.261 |
| FAC (%) | 39.2 (± 9.8) | Pearson r=-0.19 [-0.52, 0.18]; p=0.308 | 40.8 (± 8.9) | 39.1 (± 10.8) | 34.1 (± 1.2) | 0.630 | 0.308 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.937; Levene p=0.379 |
| RV-FWLS (%) | 18.2 (± 3.8) | Pearson r=-0.24 [-0.56, 0.14]; p=0.212 | 18.9 (± 4.0) | 18.2 (± 3.9) | 18.1 (± 0.1) | 0.871 | 0.212 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.546; Levene p=0.117 |
| PASP (mmHg) | 32.8 (± 10.7) | Pearson r=0.09 [-0.28, 0.44]; p=0.637 | 32.4 (± 10.2) | 34.2 (± 11.5) | 32.0 (± 18.4) | 0.901 | 0.637 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.493; Levene p=0.402 |
| RV coupling (TAPSE/PASP) | 0.64 (± 0.32) | Spearman rho=-0.02; p=0.920 | 0.64 (± 0.34) | 0.65 (± 0.26) | 0.87 (± 0.70) | 0.950 | 0.920 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.005; Levene p=0.251 |
| TR vena contracta (mm) | 3.2 (± 2.6) | Spearman rho=0.07; p=0.722 | 2.6 (± 1.4) | 2.9 (± 1.9) | 8.0 (± 8.5) | 0.624 | 0.722 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.237; Levene p=<0.001 |
| IVC diameter (mm) | 17.7 (± 5.2) | Pearson r=0.21 [-0.16, 0.53]; p=0.258 | 17.1 (± 4.7) | 18.8 (± 4.8) | 18.0 (± 8.5) | 0.695 | 0.258 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.089; Levene p=0.558 |
| Echo: 12 months — Overall n=32 | group ns: 16/15/1 | ||||||||||
| Basal RV diameter (mm) | 43.8 (± 6.6) | Pearson r=0.09 [-0.28, 0.44]; p=0.626 | 43.7 (± 7.6) | 43.9 (± 6.1) | 47.0 (± NA) | 0.901 | 0.626 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.255; Levene p=0.482 |
| Right atrium area (cm²) | 28.1 (± 8.9) | Pearson r=0.11 [-0.26, 0.45]; p=0.559 | 26.9 (± 10.1) | 29.4 (± 8.3) | 30.0 (± NA) | 0.768 | 0.559 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.240; Levene p=0.555 |
| TAPSE (mm) | 18.7 (± 4.4) | Pearson r=-0.06 [-0.41, 0.30]; p=0.742 | 18.3 (± 3.7) | 19.6 (± 5.2) | 14.0 (± NA) | 0.409 | 0.742 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.248; Levene p=0.151 |
| S' Wave (cm/s) | 10.0 (± 2.4) | Pearson r=-0.05 [-0.40, 0.32]; p=0.789 | 9.7 (± 2.4) | 10.4 (± 2.4) | 6.7 (± NA) | 0.235 | 0.789 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.040; Levene p=0.570 |
| FAC (%) | 41.5 (± 10.1) | Spearman rho=0.07; p=0.727 | 40.2 (± 7.7) | 42.8 (± 12.5) | 34.0 (± NA) | 0.296 | 0.727 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.038; Levene p=0.443 |
| RV-FWLS (%) | 18.3 (± 4.7) | Pearson r=-0.21 [-0.55, 0.18]; p=0.286 | 18.9 (± 4.8) | 18.4 (± 4.4) | 9.6 (± NA) | 0.171 | 0.286 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.976; Levene p=0.452 |
| PASP (mmHg) | 33.9 (± 11.1) | Pearson r=0.01 [-0.35, 0.37]; p=0.956 | 34.9 (± 9.7) | 33.0 (± 13.4) | 30.0 (± NA) | 0.857 | 0.956 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.347; Levene p=0.300 |
| RV coupling (TAPSE/PASP) | 0.62 (± 0.28) | Spearman rho=-0.03; p=0.881 | 0.56 (± 0.18) | 0.71 (± 0.37) | 0.47 (± NA) | 0.558 | 0.881 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.018; Levene p=0.111 |
| TR vena contracta (mm) | 3.9 (± 2.3) | Spearman rho=0.12; p=0.517 | 3.9 (± 1.8) | 3.6 (± 2.0) | 11.0 (± NA) | 0.003 | 0.517 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.088; Levene p=0.169 |
| IVC diameter (mm) | 17.6 (± 5.5) | Pearson r=0.23 [-0.14, 0.55]; p=0.217 | 17.8 (± 5.4) | 16.6 (± 5.0) | 30.0 (± NA) | 0.060 | 0.217 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.618; Levene p=0.585 |
| 1 Continuous association: Pearson if both variables pass Shapiro-Wilk; otherwise Spearman. Binary rows: t-test if residual normality and Levene are adequate; otherwise Wilcoxon rank-sum. | ||||||||||
| 2 Group comparison: continuous variables use ANOVA if residual normality and variance homogeneity hold; otherwise Kruskal-Wallis. Binary variables use chi-squared when expected counts are adequate; otherwise Fisher exact. | ||||||||||
2.2.1 Nota estadística
Contraste por grupos de LS (p value) y asociación con LS continua (p (LS)).
Resultados con p<0.05: TR vena contracta (mm) [Echo: 12 months].
2.3 Variables de laboratorio por LS
| Laboratory variables by liver stiffness | ||||||||||
| LS groups: LS≤6 kPa, 6<LS≤10 kPa, LS≥10 kPa. The continuous LS association is shown after Overall. | ||||||||||
| Variable | Overall | LS continuous association1 |
Group comparison by LS category
|
p (LS) | Group test2 | Assumption tests | Assumption results | |||
|---|---|---|---|---|---|---|---|---|---|---|
| LS≤6 kPa | 6 < LS ≤ 10 kPa | LS ≥ 10 kPa | p value | |||||||
| Laboratory: Baseline — Overall n=37 | group ns: 10/18/9 | ||||||||||
| Hemoglobine (g/dL) | 13.7 (± 1.6) | Spearman rho=-0.16; p=0.357 | 14.1 (± 1.8) | 13.6 (± 1.6) | 13.6 (± 1.7) | 0.707 | 0.357 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.871; Levene p=0.975 |
| Platelets (x 10³/mm³) | 176 (± 53) | Spearman rho=0.11; p=0.512 | 178 (± 49) | 168 (± 48) | 189 (± 69) | 0.656 | 0.512 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.563; Levene p=0.579 |
| Creatinine (mg/dL) | 1.14 (0.90-1.40) | Spearman rho=0.03; p=0.874 | 1.03 (0.90-1.28) | 1.14 (0.95-1.42) | 1.17 (0.95-1.56) | 0.524 | 0.874 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.582 |
| NT-proBNP (pg/ml) | 2032 (1000-3500) | Spearman rho=-0.09; p=0.612 | 1872 (1030-4363) | 1713 (1082-3406) | 3067 (942-3434) | 0.994 | 0.612 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.645 |
| Alkaline Phosphatase (IU/L) | 94 (± 38) | Spearman rho=0.03; p=0.870 | 105 (± 43) | 84 (± 39) | 99 (± 32) | 0.393 | 0.870 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.377; Levene p=0.590 |
| ALT (IU/L) | 20.0 (18.0-27.0) | Spearman rho=0.25; p=0.137 | 20.0 (18.0-29.2) | 19.0 (16.2-24.8) | 23.0 (19.0-32.0) | 0.465 | 0.137 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.763 |
| AST (IU/L) | 26.0 (22.0-33.0) | Spearman rho=0.21; p=0.207 | 26.5 (22.2-38.0) | 23.5 (20.0-26.8) | 31.0 (25.0-35.0) | 0.042 | 0.207 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.156; Levene p=0.284 |
| GGT (IU/L) | 43.0 (27.0-145.0) | Spearman rho=0.41; p=0.012 | 42.0 (21.8-91.2) | 35.5 (27.0-105.8) | 145.0 (122.0-183.0) | 0.043 | 0.012 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.620 |
| Bilirrubine (mg/dL) | 0.9 (0.7-1.2) | Spearman rho=-0.02; p=0.901 | 0.8 (0.7-1.1) | 1.1 (0.7-1.4) | 0.7 (0.7-0.9) | 0.337 | 0.901 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.589 |
| Laboratory: 1 month — Overall n=30 | group ns: 16/12/2 | ||||||||||
| Hemoglobine (g/dL) | 13.6 (± 1.6) | Pearson r=-0.33 [-0.63, 0.05]; p=0.085 | 13.8 (± 0.5) | 12.8 (± 1.8) | 13.3 (± 4.2) | 0.157 | 0.085 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.026; Levene p=<0.001 |
| Platelets (x 10³/mm³) | 185 (± 57) | Pearson r=-0.37 [-0.65, 0.00]; p=0.051 | 201 (± 65) | 166 (± 38) | 146 (± 35) | 0.172 | 0.051 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.964; Levene p=0.128 |
| Creatinine (mg/dL) | 1.10 (0.95-1.40) | Spearman rho=0.25; p=0.179 | 1.00 (0.89-1.25) | 1.18 (1.08-1.51) | 1.18 (1.11-1.24) | 0.178 | 0.179 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.431 |
| NT-proBNP (pg/ml) | 2045 (1040-3888) | Spearman rho=0.14; p=0.451 | 1270 (879-3016) | 2141 (1372-3758) | 1687 (1334-2040) | 0.568 | 0.451 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.593 |
| Alkaline Phosphatase (IU/L) | 95 (± 41) | Pearson r=-0.26 [-0.57, 0.13]; p=0.188 | 95 (± 40) | 87 (± 36) | 84 (± 50) | 0.831 | 0.188 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.921; Levene p=0.819 |
| ALT (IU/L) | 18.0 (15.5-25.0) | Spearman rho=0.20; p=0.286 | 16.0 (13.8-19.8) | 20.0 (17.0-40.0) | 28.0 (24.0-32.0) | 0.089 | 0.286 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.001; Levene p=0.242 |
| AST (IU/L) | 27.0 (22.0-30.5) | Pearson r=0.06 [-0.31, 0.41]; p=0.769 | 25.0 (20.0-30.0) | 26.5 (22.5-30.8) | 30.5 (27.2-33.8) | 0.659 | 0.769 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.859; Levene p=0.733 |
| GGT (IU/L) | 51.0 (24.0-100.5) | Spearman rho=0.10; p=0.595 | 37.0 (20.8-56.2) | 57.5 (30.8-158.0) | 84.0 (59.0-109.0) | 0.165 | 0.595 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.166 |
| Bilirrubine (mg/dL) | 0.9 (0.6-1.1) | Spearman rho=-0.14; p=0.472 | 0.9 (0.6-1.1) | 1.0 (0.6-1.2) | 0.7 (0.6-0.8) | 0.640 | 0.472 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.002; Levene p=0.539 |
| Laboratory: 12 months — Overall n=32 | group ns: 16/15/1 | ||||||||||
| Hemoglobine (g/dL) | 14.2 (± 1.3) | Spearman rho=0.08; p=0.668 | 13.8 (± 0.8) | 14.5 (± 1.7) | 14.4 (± NA) | 0.545 | 0.668 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.006; Levene p=0.161 |
| Platelets (x 10³/mm³) | 179 (± 48) | Pearson r=0.04 [-0.33, 0.40]; p=0.849 | 172 (± 56) | 183 (± 41) | 144 (± NA) | 0.656 | 0.849 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.735; Levene p=0.325 |
| Creatinine (mg/dL) | 1.20 (0.96-1.54) | Spearman rho=0.04; p=0.856 | 1.10 (1.00-1.40) | 1.20 (0.95-1.60) | 1.51 (1.51-1.51) | 0.743 | 0.856 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.757 |
| NT-proBNP (pg/ml) | 2032 (1000-3500) | Spearman rho=-0.23; p=0.212 | 2328 (1522-3854) | 1101 (912-2440) | 3434 (3434-3434) | 0.122 | 0.212 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.351 |
| Alkaline Phosphatase (IU/L) | 97 (± 39) | Pearson r=0.19 [-0.19, 0.52]; p=0.331 | 90 (± 43) | 105 (± 36) | 111 (± NA) | 0.599 | 0.331 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.128; Levene p=0.529 |
| ALT (IU/L) | 18.5 (16.0-25.5) | Spearman rho=0.14; p=0.480 | 17.0 (15.0-24.0) | 20.0 (17.0-26.0) | 26.0 (26.0-26.0) | 0.448 | 0.480 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.763 |
| AST (IU/L) | 24.0 (18.0-34.0) | Spearman rho=0.08; p=0.698 | 22.5 (16.8-27.2) | 24.0 (18.5-29.5) | 42.0 (42.0-42.0) | 0.340 | 0.698 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.567 |
| GGT (IU/L) | 48.5 (23.2-129.2) | Spearman rho=0.28; p=0.139 | 37.0 (18.0-125.0) | 65.0 (34.5-137.0) | 130.0 (130.0-130.0) | 0.293 | 0.139 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.715 |
| Bilirrubine (mg/dL) | 0.9 (0.7-1.1) | Spearman rho=0.16; p=0.403 | 0.8 (0.6-1.0) | 0.9 (0.8-1.2) | 1.2 (1.2-1.2) | 0.191 | 0.403 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.018; Levene p=0.218 |
| 1 Continuous association: Pearson if both variables pass Shapiro-Wilk; otherwise Spearman. Binary rows: t-test if residual normality and Levene are adequate; otherwise Wilcoxon rank-sum. | ||||||||||
| 2 Group comparison: continuous variables use ANOVA if residual normality and variance homogeneity hold; otherwise Kruskal-Wallis. Binary variables use chi-squared when expected counts are adequate; otherwise Fisher exact. | ||||||||||
2.3.1 Nota estadística
Contraste por grupos de LS (p value) y asociación con LS continua (p (LS)).
Resultados con p<0.05: AST (IU/L) [Laboratory: Baseline]; GGT (IU/L) [Laboratory: Baseline].
3 Tabla 1 estilo manuscrito: características basales
Tabla basal por grupos de LS para el manuscrito.
| Table 1. Baseline characteristics by baseline liver stiffness | ||||||||||
| This table is generated from the canonical harmonised dataset. | ||||||||||
| Variable | Overall | LS continuous association1 |
Group comparison by LS category
|
p (LS) | Group test2 | Assumption tests | Assumption results | |||
|---|---|---|---|---|---|---|---|---|---|---|
| LS≤6 kPa | 6 < LS ≤ 10 kPa | LS ≥ 10 kPa | p value | |||||||
| Table 1: Baseline — Overall n=37 | group ns: 10/18/9 | ||||||||||
| Age (years) | 77 (74-81) | Spearman rho=-0.08; p=0.636 | 78 (76-81) | 76 (71-81) | 75 (74-82) | 0.875 | 0.636 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.945 |
| Female (nº, %) | 22 (59%) | Wilcoxon rank-sum median delta=0.78 kPa; p=0.938 | 6 (60%) | 12 (67%) | 4 (44%) | 0.622 | 0.938 | Fisher exact | Expected counts | min expected=3.65 (<5) |
| Hypertension (nº, %) | 22 (59%) | Wilcoxon rank-sum median delta=-1.13 kPa; p=0.516 | 7 (70%) | 9 (50%) | 6 (67%) | 0.570 | 0.516 | Fisher exact | Expected counts | min expected=3.65 (<5) |
| Hyperlipidaemia (nº, %) | 13 (35%) | Wilcoxon rank-sum median delta=2.45 kPa; p=0.445 | 3 (30%) | 5 (28%) | 5 (56%) | 0.360 | 0.445 | Fisher exact | Expected counts | min expected=3.16 (<5) |
| Diabetes mellitus (nº, %) | 8 (22%) | Wilcoxon rank-sum median delta=-0.50 kPa; p=0.810 | 3 (30%) | 3 (17%) | 2 (22%) | 0.872 | 0.810 | Fisher exact | Expected counts | min expected=1.95 (<5) |
| Atrial fibrillation (nº, %) | 34 (92%) | Wilcoxon rank-sum median delta=-1.23 kPa; p=0.759 | 9 (90%) | 16 (89%) | 9 (100%) | 0.792 | 0.759 | Fisher exact | Expected counts | min expected=0.73 (<5) |
| Ischemic cardiomyopathy (nº, %) | 6 (16%) | Wilcoxon rank-sum median delta=0.02 kPa; p=0.757 | 2 (20%) | 2 (11%) | 2 (22%) | 0.613 | 0.757 | Fisher exact | Expected counts | min expected=1.46 (<5) |
| Aortic valve surgery (nº, %) | 7 (19%) | Wilcoxon rank-sum median delta=2.83 kPa; p=0.771 | 2 (20%) | 2 (11%) | 3 (33%) | 0.353 | 0.771 | Fisher exact | Expected counts | min expected=1.70 (<5) |
| TAVR (nº, %) | 3 (8%) | Wilcoxon rank-sum median delta=4.33 kPa; p=0.210 | 0 (0%) | 1 (6%) | 2 (22%) | 0.208 | 0.210 | Fisher exact | Expected counts | min expected=0.73 (<5) |
| Mitral valve surgery (nº, %) | 13 (35%) | Wilcoxon rank-sum median delta=1.13 kPa; p=0.987 | 5 (50%) | 5 (28%) | 3 (33%) | 0.555 | 0.987 | Fisher exact | Expected counts | min expected=3.16 (<5) |
| Chronic Kidney Disease (nº, %) | 16 (43%) | Wilcoxon rank-sum median delta=-0.17 kPa; p=0.878 | 4 (40%) | 8 (44%) | 4 (44%) | 1.000 | 0.878 | Fisher exact | Expected counts | min expected=3.89 (<5) |
| Number of diuretics | 1.6 (± 0.8) | Spearman rho=-0.03; p=0.882 | 1.7 (± 0.7) | 1.4 (± 0.8) | 1.8 (± 0.8) | 0.386 | 0.882 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.084; Levene p=0.802 |
| NYHA ≥3 (nº, %) | 24 (65%) | Wilcoxon rank-sum median delta=-1.25 kPa; p=0.656 | 7 (70%) | 12 (67%) | 5 (56%) | 0.818 | 0.656 | Fisher exact | Expected counts | min expected=3.16 (<5) |
| Edema (nº, %) | 21 (57%) | Wilcoxon rank-sum median delta=0.17 kPa; p=0.668 | 5 (50%) | 10 (56%) | 6 (67%) | 0.832 | 0.668 | Fisher exact | Expected counts | min expected=3.89 (<5) |
| Ascitis (nº, %) | 10 (27%) | Wilcoxon rank-sum median delta=0.00 kPa; p=0.824 | 3 (30%) | 4 (22%) | 3 (33%) | 0.801 | 0.824 | Fisher exact | Expected counts | min expected=2.43 (<5) |
| Diuretic resistance (nº, %) | 10 (43%) | t-test delta=0.14 kPa [-2.86, 2.58]; p=0.917 | 3 (60%) | 4 (33%) | 3 (50%) | 0.637 | 0.917 | Fisher exact | Expected counts | min expected=2.17 (<5) |
| MELD-XI | 13.1 (± 3.8) | Spearman rho=-0.05; p=0.769 | 12.2 (± 2.7) | 13.8 (± 4.4) | 12.9 (± 3.5) | 0.697 | 0.769 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.003; Levene p=0.661 |
| FIB-4 score | 2.7 (± 1.3) | Spearman rho=-0.02; p=0.889 | 3.0 (± 1.9) | 2.5 (± 1.1) | 2.8 (± 1.0) | 0.568 | 0.889 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.006; Levene p=0.465 |
| VEXUS ≥2 (nº, %) | 23 (62%) | t-test delta=1.97 kPa [-3.90, -0.03]; p=0.046 | 3 (30%) | 13 (72%) | 7 (78%) | 0.058 | 0.046 | Fisher exact | Expected counts | min expected=3.41 (<5) |
| LVEF (%) | 57.5 (± 8.2) | Spearman rho=-0.08; p=0.658 | 59.3 (± 9.2) | 57.6 (± 7.1) | 55.6 (± 9.6) | 0.633 | 0.658 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.581; Levene p=0.715 |
| Basal RV diameter (mm) | 47.2 (± 5.8) | Spearman rho=0.09; p=0.597 | 45.6 (± 5.0) | 48.2 (± 6.4) | 47.0 (± 5.7) | 0.548 | 0.597 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.780; Levene p=0.645 |
| Right atrium area (cm²) | 28.8 (± 7.6) | Spearman rho=0.15; p=0.376 | 24.1 (± 10.4) | 31.4 (± 6.3) | 28.9 (± 3.6) | 0.052 | 0.376 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.145; Levene p=0.241 |
| TAPSE (mm) | 18.2 (± 5.2) | Spearman rho=-0.14; p=0.419 | 18.0 (± 4.1) | 18.8 (± 6.4) | 17.3 (± 3.4) | 0.775 | 0.419 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.325; Levene p=0.296 |
| S' Wave (cm/s) | 10.7 (± 2.5) | Spearman rho=0.02; p=0.907 | 10.7 (± 2.3) | 10.7 (± 2.7) | 10.8 (± 2.9) | 0.993 | 0.907 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.984; Levene p=0.965 |
| FAC (%) | 38.2 (± 8.7) | Spearman rho=-0.24; p=0.152 | 39.3 (± 3.3) | 39.5 (± 9.0) | 34.2 (± 11.4) | 0.314 | 0.152 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.562; Levene p=0.021 |
| RV-FWLS (%) | 19.9 (± 4.6) | Spearman rho=-0.08; p=0.656 | 20.1 (± 3.7) | 19.8 (± 5.5) | 19.8 (± 4.2) | 0.985 | 0.656 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.163; Levene p=0.540 |
| PASP (mmHg) | 33.3 (± 10.1) | Spearman rho=0.05; p=0.794 | 33.6 (± 9.3) | 31.3 (± 10.3) | 36.1 (± 11.2) | 0.601 | 0.794 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.118; Levene p=0.762 |
| RV coupling (TAPSE/PASP) | 0.63 (± 0.26) | Spearman rho=-0.09; p=0.659 | 0.54 (± 0.13) | 0.76 (± 0.29) | 0.52 (± 0.22) | 0.065 | 0.659 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.986; Levene p=0.155 |
| TR vena contracta (mm) | 11.2 (± 3.4) | Spearman rho=0.15; p=0.390 | 10.7 (± 4.2) | 11.0 (± 3.0) | 12.2 (± 3.3) | 0.459 | 0.390 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=0.005; Levene p=0.897 |
| GAP (mm) | 6.9 (± 1.7) | Spearman rho=0.26; p=0.130 | 6.3 (± 1.5) | 6.9 (± 1.5) | 7.7 (± 2.1) | 0.245 | 0.130 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.591; Levene p=0.544 |
| TR massive/torrential (nº, %) | 12 (32%) | Wilcoxon rank-sum median delta=2.45 kPa; p=0.194 | 2 (20%) | 6 (33%) | 4 (44%) | 0.533 | 0.194 | Fisher exact | Expected counts | min expected=2.92 (<5) |
| IVC diameter (mm) | 23.0 (± 3.8) | Spearman rho=-0.02; p=0.920 | 23.5 (± 4.9) | 22.9 (± 3.8) | 22.9 (± 2.7) | 0.920 | 0.920 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.133; Levene p=0.310 |
| Hemoglobine (g/dL) | 13.7 (± 1.6) | Spearman rho=-0.16; p=0.357 | 14.1 (± 1.8) | 13.6 (± 1.6) | 13.6 (± 1.7) | 0.707 | 0.357 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.871; Levene p=0.975 |
| Platelets (x 10³/mm³) | 176 (± 53) | Spearman rho=0.11; p=0.512 | 178 (± 49) | 168 (± 48) | 189 (± 69) | 0.656 | 0.512 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.563; Levene p=0.579 |
| Creatinine (mg/dL) | 1.14 (0.90-1.40) | Spearman rho=0.03; p=0.874 | 1.03 (0.90-1.28) | 1.14 (0.95-1.42) | 1.17 (0.95-1.56) | 0.524 | 0.874 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.582 |
| NT-proBNP (pg/ml) | 2032 (1000-3500) | Spearman rho=-0.09; p=0.612 | 1872 (1030-4363) | 1713 (1082-3406) | 3067 (942-3434) | 0.994 | 0.612 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.645 |
| Alkaline Phosphatase (IU/L) | 94 (± 38) | Spearman rho=0.03; p=0.870 | 105 (± 43) | 84 (± 39) | 99 (± 32) | 0.393 | 0.870 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.377; Levene p=0.590 |
| ALT (IU/L) | 20.0 (18.0-27.0) | Spearman rho=0.25; p=0.137 | 20.0 (18.0-29.2) | 19.0 (16.2-24.8) | 23.0 (19.0-32.0) | 0.465 | 0.137 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.763 |
| AST (IU/L) | 26.0 (22.0-33.0) | Spearman rho=0.21; p=0.207 | 26.5 (22.2-38.0) | 23.5 (20.0-26.8) | 31.0 (25.0-35.0) | 0.042 | 0.207 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.156; Levene p=0.284 |
| GGT (IU/L) | 43.0 (27.0-145.0) | Spearman rho=0.41; p=0.012 | 42.0 (21.8-91.2) | 35.5 (27.0-105.8) | 145.0 (122.0-183.0) | 0.043 | 0.012 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.620 |
| Bilirrubine (mg/dL) | 0.9 (0.7-1.2) | Spearman rho=-0.02; p=0.901 | 0.8 (0.7-1.1) | 1.1 (0.7-1.4) | 0.7 (0.7-0.9) | 0.337 | 0.901 | Kruskal-Wallis | Shapiro-Wilk residuals; Levene | Shapiro p=<0.001; Levene p=0.589 |
| PASP invasive (mmHg) | 33.3 (± 10.1) | Spearman rho=0.05; p=0.794 | 33.6 (± 9.3) | 31.3 (± 10.3) | 36.1 (± 11.2) | 0.601 | 0.794 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.118; Levene p=0.762 |
| PAMP (mmHg) | 21.1 (± 7.0) | Spearman rho=0.02; p=0.903 | 21.6 (± 6.6) | 20.6 (± 7.2) | 21.4 (± 7.7) | 0.955 | 0.903 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.723; Levene p=0.766 |
| RV coupling invasive | 0.63 (± 0.26) | Spearman rho=-0.09; p=0.659 | 0.54 (± 0.13) | 0.76 (± 0.29) | 0.52 (± 0.22) | 0.065 | 0.659 | ANOVA | Shapiro-Wilk residuals; Levene | Shapiro p=0.986; Levene p=0.155 |
| 1 Continuous association: Pearson if both variables pass Shapiro-Wilk; otherwise Spearman. Binary rows: t-test if residual normality and Levene are adequate; otherwise Wilcoxon rank-sum. | ||||||||||
| 2 Group comparison: continuous variables use ANOVA if residual normality and variance homogeneity hold; otherwise Kruskal-Wallis. Binary variables use chi-squared when expected counts are adequate; otherwise Fisher exact. | ||||||||||
3.0.1 Nota estadística
Tabla basal por grupos de LS. Se muestran contraste categórico por grupos y asociación con LS continua.
Resultados con p<0.05: AST (IU/L) [Table 1: Baseline]; GGT (IU/L) [Table 1: Baseline].
4 Tabla de medidas repetidas
Análisis longitudinal de LS continua en los tres momentos.
4.1 Análisis global de LS continua
| Repeated-measures ANOVA for liver stiffness | ||||||
| Effect | DFn | DFd | F | p value | Partial eta² | Complete cases |
|---|---|---|---|---|---|---|
| Time | 2 | 52 | 7.88 | 0.001 | 0.233 | 27 |
| Post hoc paired comparisons for liver stiffness | ||||||
| Comparison | n | Mean change (kPa) | 95% CI | paired t | p Holm | Wilcoxon p Holm |
|---|---|---|---|---|---|---|
| Baseline -> 1 month | 27 | -1.74 | [-2.81, -0.67] | -3.34 | 0.007 | 0.006 |
| Baseline -> 12 months | 27 | -1.86 | [-2.99, -0.73] | -3.38 | 0.007 | 0.004 |
| 1 month -> 12 months | 27 | -0.12 | [-1.15, 0.91] | -0.24 | 0.809 | 0.840 |
ANOVA de medidas repetidas con casos completos (27). Contrastes post hoc pareados con ajuste de Holm.
Figura del ANOVA: líneas grises = pacientes; puntos negros y barras = media e IC 95%; brackets = p ajustadas por Holm.
Tabla longitudinal: contrastes pareados frente a basal y test global cuando hay tres momentos.
| Table 2. Clinical, laboratory and echo parameters at baseline, 1 month and 12 months | |||||||||
| Variable | Baseline | 1 month | p (B–1m) | 12 months | p (B–12m) | Global p | Pairwise tests | Global test | Assumption notes |
|---|---|---|---|---|---|---|---|---|---|
| Clinical | |||||||||
| NYHA ≥3 (nº, %) | 24 (65%) (n=37) | 2 (6%) (n=36) | <0.001 | 4 (12%) (n=33) | <0.001 | <0.001 | B-1m: McNemar; B-12m: McNemar | Cochran's Q | B-1m: Discordant=21 | B-12m: Discordant=17 | Global: n=33 |
| Edema (nº, %) | 21 (57%) (n=37) | 7 (19%) (n=36) | 0.004 | 4 (12%) (n=33) | 0.002 | <0.001 | B-1m: McNemar; B-12m: McNemar | Cochran's Q | B-1m: Discordant=17 | B-12m: Discordant=15 | Global: n=33 |
| Ascitis (nº, %) | 10 (27%) (n=37) | 1 (3%) (n=36) | 0.013 | 1 (3%) (n=33) | 0.046 | 0.002 | B-1m: McNemar; B-12m: McNemar | Cochran's Q | B-1m: Discordant=8 | B-12m: Discordant=9 | Global: n=33 |
| Elastography (kPa) | 7.2 (6.0-10.0) (n=37) | 5.7 (4.7-7.5) (n=30) | <0.001 | 6.0 (4.7-7.5) (n=32) | 0.001 | 0.002 | B-1m: Paired t-test; B-12m: Wilcoxon signed-rank | Friedman | B-1m: Shapiro(diff) p=0.549 | B-12m: Shapiro(diff) p=0.002 | Global: Shapiro diffs p=0.532, 0.013, 0.863 |
| VEXUS (nº) | 2 (1-2) (n=37) | 1 (0-2) (n=30) | 0.036 | 0 (0-1) (n=31) | 0.004 | 0.037 | B-1m: Wilcoxon signed-rank; B-12m: Paired t-test | Friedman | B-1m: Shapiro(diff) p=0.033 | B-12m: Shapiro(diff) p=0.189 | Global: Shapiro diffs p=0.071, 0.265, <0.001 |
| Echo parameters | |||||||||
| Basal RV diameter (mm) | 47.2 (± 5.8) (n=37) | 45.1 (± 6.1) (n=36) | 0.009 | 43.8 (± 6.6) (n=31) | <0.001 | 0.003 | B-1m: Wilcoxon signed-rank; B-12m: Paired t-test | Friedman | B-1m: Shapiro(diff) p=0.009 | B-12m: Shapiro(diff) p=0.944 | Global: Shapiro diffs p=0.003, 0.944, 0.164 |
| Right atrium area (cm²) | 28.8 (± 7.6) (n=37) | 27.9 (± 5.9) (n=35) | 0.348 | 28.1 (± 8.9) (n=31) | 0.210 | 0.536 | B-1m: Paired t-test; B-12m: Wilcoxon signed-rank | Friedman | B-1m: Shapiro(diff) p=0.752 | B-12m: Shapiro(diff) p=0.001 | Global: Shapiro diffs p=0.705, 0.001, 0.006 |
| TAPSE (mm) | 18.0 (15.0-21.0) (n=37) | 18.0 (16.0-21.2) (n=36) | 0.737 | 18.0 (16.5-21.5) (n=31) | 0.852 | 0.834 | B-1m: Paired t-test; B-12m: Paired t-test | Friedman | B-1m: Shapiro(diff) p=0.660 | B-12m: Shapiro(diff) p=0.188 | Global: Shapiro diffs p=0.778, 0.188, 0.005 |
| S' Wave (cm/s) | 10.9 (9.0-12.1) (n=36) | 9.5 (8.5-11.8) (n=36) | 0.041 | 9.5 (8.4-11.5) (n=31) | 0.021 | 0.008 | B-1m: Paired t-test; B-12m: Paired t-test | RM-ANOVA (GG) | B-1m: Shapiro(diff) p=0.704 | B-12m: Shapiro(diff) p=0.056 | Global: Shapiro diffs p=0.411, 0.056, 0.136 |
| FAC (%) | 38.2 (± 8.7) (n=37) | 39.2 (± 9.8) (n=36) | 0.690 | 41.5 (± 10.1) (n=31) | 0.035 | 0.264 | B-1m: Paired t-test; B-12m: Wilcoxon signed-rank | Friedman | B-1m: Shapiro(diff) p=0.091 | B-12m: Shapiro(diff) p=<0.001 | Global: Shapiro diffs p=0.018, <0.001, 0.025 |
| RV-FWLS (%) | 19.9 (± 4.6) (n=36) | 18.2 (± 3.8) (n=34) | 0.025 | 18.3 (± 4.7) (n=28) | 0.154 | 0.091 | B-1m: Paired t-test; B-12m: Paired t-test | RM-ANOVA (GG) | B-1m: Shapiro(diff) p=0.766 | B-12m: Shapiro(diff) p=0.719 | Global: Shapiro diffs p=0.348, 0.569, 0.496 |
| PASP (mmHg) | 33.3 (± 10.1) (n=27) | 32.8 (± 10.7) (n=36) | 0.870 | 33.9 (± 11.1) (n=31) | 0.430 | 0.696 | B-1m: Paired t-test; B-12m: Paired t-test | RM-ANOVA (GG) | B-1m: Shapiro(diff) p=0.653 | B-12m: Shapiro(diff) p=0.633 | Global: Shapiro diffs p=0.524, 0.633, 0.110 |
| TR vena contracta (mm) | 10.0 (8.9-13.0) (n=37) | 2.8 (2.0-4.0) (n=36) | <0.001 | 4.0 (2.0-5.0) (n=31) | <0.001 | <0.001 | B-1m: Wilcoxon signed-rank; B-12m: Wilcoxon signed-rank | Friedman | B-1m: Shapiro(diff) p=0.025 | B-12m: Shapiro(diff) p=0.001 | Global: Shapiro diffs p=0.027, 0.001, 0.009 |
| IVC diameter (mm) | 23.0 (± 3.8) (n=36) | 17.7 (± 5.2) (n=36) | <0.001 | 17.6 (± 5.5) (n=31) | <0.001 | <0.001 | B-1m: Paired t-test; B-12m: Paired t-test | RM-ANOVA (GG) | B-1m: Shapiro(diff) p=0.272 | B-12m: Shapiro(diff) p=0.217 | Global: Shapiro diffs p=0.244, 0.217, 0.076 |
| Laboratory parameters | |||||||||
| Hemoglobine (g/dL) | 13.7 (± 1.6) (n=37) | 13.6 (± 1.6) (n=33) | 0.772 | 14.2 (± 1.3) (n=30) | 0.006 | 0.022 | B-1m: Paired t-test; B-12m: Paired t-test | RM-ANOVA (GG) | B-1m: Shapiro(diff) p=0.080 | B-12m: Shapiro(diff) p=0.519 | Global: Shapiro diffs p=0.293, 0.807, 0.401 |
| Platelets (x 10³/mm³) | 176 (± 53) (n=37) | 185 (± 57) (n=33) | 0.097 | 179 (± 48) (n=30) | 0.555 | 0.478 | B-1m: Paired t-test; B-12m: Paired t-test | RM-ANOVA (GG) | B-1m: Shapiro(diff) p=0.814 | B-12m: Shapiro(diff) p=0.506 | Global: Shapiro diffs p=0.487, 0.433, 0.836 |
| Creatinine (mg/dL) | 1.14 (0.90-1.40) (n=37) | 1.10 (0.95-1.40) (n=35) | 0.655 | 1.20 (0.96-1.54) (n=30) | 0.012 | 0.009 | B-1m: Wilcoxon signed-rank; B-12m: Wilcoxon signed-rank | Friedman | B-1m: Shapiro(diff) p=<0.001 | B-12m: Shapiro(diff) p=<0.001 | Global: Shapiro diffs p=<0.001, <0.001, <0.001 |
| NT-proBNP (pg/ml) | 2032 (1000-3500) (n=37) | 2045 (1040-3888) (n=35) | 0.676 | 2032 (1000-3500) (n=37) | NA | 0.972 | B-1m: Wilcoxon signed-rank; B-12m: Wilcoxon signed-rank | Friedman | B-1m: Shapiro(diff) p=<0.001 | B-12m: Shapiro(diff) p=NA | Global: Shapiro diffs p=<0.001, NA, <0.001 |
| Alkaline Phosphatase (IU/L) | 94 (± 38) (n=34) | 95 (± 41) (n=33) | 0.965 | 97 (± 39) (n=30) | 0.395 | 0.130 | B-1m: Wilcoxon signed-rank; B-12m: Paired t-test | Friedman | B-1m: Shapiro(diff) p=<0.001 | B-12m: Shapiro(diff) p=0.169 | Global: Shapiro diffs p=<0.001, 0.136, <0.001 |
| ALT (IU/L) | 20.0 (18.0-27.0) (n=37) | 18.0 (15.5-25.0) (n=35) | 0.168 | 18.5 (16.0-25.5) (n=30) | 0.396 | 0.659 | B-1m: Wilcoxon signed-rank; B-12m: Wilcoxon signed-rank | Friedman | B-1m: Shapiro(diff) p=<0.001 | B-12m: Shapiro(diff) p=0.046 | Global: Shapiro diffs p=0.006, 0.115, 0.018 |
| AST (IU/L) | 26.0 (22.0-33.0) (n=37) | 27.0 (22.0-30.5) (n=35) | 0.768 | 24.0 (18.0-34.0) (n=29) | 0.199 | 0.102 | B-1m: Wilcoxon signed-rank; B-12m: Paired t-test | Friedman | B-1m: Shapiro(diff) p=0.019 | B-12m: Shapiro(diff) p=0.068 | Global: Shapiro diffs p=0.032, 0.048, <0.001 |
| GGT (IU/L) | 43.0 (27.0-145.0) (n=37) | 51.0 (24.0-100.5) (n=35) | 0.071 | 48.5 (23.2-129.2) (n=30) | 0.328 | 0.331 | B-1m: Wilcoxon signed-rank; B-12m: Wilcoxon signed-rank | Friedman | B-1m: Shapiro(diff) p=<0.001 | B-12m: Shapiro(diff) p=<0.001 | Global: Shapiro diffs p=0.003, <0.001, <0.001 |
| Bilirrubine (mg/dL) | 0.9 (0.7-1.2) (n=37) | 0.9 (0.6-1.1) (n=35) | 0.074 | 0.9 (0.7-1.1) (n=30) | 0.855 | 0.667 | B-1m: Paired t-test; B-12m: Wilcoxon signed-rank | Friedman | B-1m: Shapiro(diff) p=0.272 | B-12m: Shapiro(diff) p=0.003 | Global: Shapiro diffs p=0.192, 0.003, 0.016 |
4.1.1 Nota estadística
Contrastes intra-sujeto frente a basal y test global de medidas repetidas cuando procede.
Cambios longitudinales con p<0.05: NYHA ≥3 (nº, %) [Clinical]; Edema (nº, %) [Clinical]; Ascitis (nº, %) [Clinical]; Elastography (kPa) [Clinical]; VEXUS (nº) [Clinical]; Basal RV diameter (mm) [Echo parameters]; S’ Wave (cm/s) [Echo parameters]; FAC (%) [Echo parameters]; RV-FWLS (%) [Echo parameters]; TR vena contracta (mm) [Echo parameters] y 3 resultado(s) adicional(es).
5 Transiciones entre categorías de LS
| Transitions between LS categories | ||||||
| comparison | improved | worsened | unchanged | effective_n | p_sign | p_stuart_maxwell |
|---|---|---|---|---|---|---|
| Baseline -> 1 month | 11 | 2 | 17 | 13 | 0.011 | 0.039 |
| Baseline -> 12 months | 13 | 3 | 16 | 16 | 0.011 | 0.020 |
Transiciones por categorías de LS: Stuart-Maxwell para homogeneidad marginal y test binomial direccional para mejoras frente a empeoramientos.
6 Figuras finales del manuscrito
Figuras descritas en las leyendas del manuscrito. Figure 1, Figure 2 y el panel superior izquierdo de la central se dejan como espacios en blanco para ser completados por el equipo clínico.
6.1 Figure 1. Study flowchart
The diagram describes the protocol used for the enrollment of patients in the present study. LS = Liver Stiffness; T-TEER = Tricuspid Transcatheter Edge-to-Edge Repair.
6.2 Figure 2. Liver stiffness assessed by elastography
A liver portion free of large vessels should be selected, and 10 measurements should be performed. The representative value is the median of these measurements, which is considered reliable if the IQR/median ratio is less than 30%.
6.3 Figure 3. Comparison of tricuspid regurgitation severity
Comparison of tricuspid regurgitation severity at baseline, 1 month and 12 months of follow-up. Boxed labels indicate the percentage of subjects with moderate or less TR.
| Figure 3 statistical contrasts | |||||
| Contrast | n | Test | Statistic | Discordant | p value |
|---|---|---|---|---|---|
| Global change across time | 32 | Cochran's Q | 54.20 | <0.001 | |
| Baseline vs 1 month | 37 | McNemar | 31.03 | 33 | <0.001 |
| Baseline vs 12 months | 32 | McNemar | 26.04 | 28 | <0.001 |
| 1 month vs 12 months | 32 | McNemar | 0.00 | 3 | 1.000 |
6.4 Figure 4. Comparison of LS categories over follow-up
Comparison of fibrosis involvement according to LS categories at baseline, 1 month and 12 months of follow-up. Boxed labels indicate the percentage of subjects with normal LS (≤6 kPa).
| Figure 4 statistical contrasts | |||||
| Scale | Contrast | n | Test | Statistic | p value |
|---|---|---|---|---|---|
| Normal LS vs >6 kPa | Global change across time | 27 | Cochran's Q | 3.88 | 0.144 |
| Normal LS vs >6 kPa | Baseline vs 1 month | 30 | McNemar | 3.27 | 0.070 |
| Normal LS vs >6 kPa | Baseline vs 12 months | 32 | McNemar | 2.77 | 0.096 |
| Normal LS vs >6 kPa | 1 month vs 12 months | 27 | McNemar | 0.00 | 1.000 |
| 3 LS categories | Baseline vs 1 month | 30 | Stuart-Maxwell | 6.50 | 0.039 |
| 3 LS categories | Baseline vs 12 months | 32 | Stuart-Maxwell | 7.84 | 0.020 |
| 3 LS categories | 1 month vs 12 months | 27 | Stuart-Maxwell | 2.00 | 0.368 |
6.5 Figure 4. Comparison of LS categories over follow-up (Alternative)
Flows represent within-patient transitions. Green indicates improvement, grey indicates unchanged category, and red indicates worsening.
Esta figura indica algo muy parecido a la anterior, pero con contrastes sobre la proporción de transiciones, la figura anterior es útil a nivel exploratorio, pero los p valores son pobres y el contraste global de Q de Cochran no sale significativo, hay que decidir si merece más la pena mostrar el gráfico de transiciones que os pongo aquí abajo.
| Figure 4 alternative statistical contrasts | ||||||
| Contrast | Improved | Worsened | Unchanged | Effective n | Improvement sign test p | Stuart-Maxwell p |
|---|---|---|---|---|---|---|
| Baseline -> 1 month | 11 | 2 | 17 | 13 | 0.011 | 0.039 |
| Baseline -> 12 months | 13 | 3 | 16 | 16 | 0.011 | 0.020 |
6.6 Figure 5. Individual trajectories of LS over time
This graphic shows the evolution of LS of each individual subject. It suggests heterogeneous responses, with several patients showing reductions over time and others remaining stable or increasing modestly.
6.7 Figure 6. Baseline LS and follow-up LS
Scatterplot showing the relationship between baseline LS and LS change at 1 month and 12 months. The y-axis represents follow-up LS minus baseline LS; values below zero indicate LS reduction. Smoothed curves display the association between baseline LS and change in LS. Boxed labels show paired t-test statistics and Holm-adjusted p values.
6.8 Figure 7. Functional class according to NYHA classification
Functional class according to NYHA classification at baseline, 1 month and 12 months of follow-up. Boxed labels indicate the percentage of subjects in NYHA class I/II.
| Figure 7 statistical contrasts | |||||
| Contrast | n | Test | Statistic | Discordant | p value |
|---|---|---|---|---|---|
| Global change across time | 33 | Cochran's Q | 33.24 | <0.001 | |
| Baseline vs 1 month | 36 | McNemar | 19.05 | 21 | <0.001 |
| Baseline vs 12 months | 33 | McNemar | 15.06 | 17 | <0.001 |
| 1 month vs 12 months | 33 | McNemar | 0.80 | 5 | 0.371 |
6.9 Central illustration
Upper-left panel left blank for the clinical summary. Upper-right panel: 1-month LS change by baseline LS. Lower panel: LS category transitions.
6.10 Central illustration
Upper-left panel left blank for the clinical summary. Upper-right panel: 1-month LS change by baseline LS. Lower panel: LS category transitions.
7 Otras posibles figuras
Figuras exploratorias adicionales para selección o material suplementario.
7.1 Distribución longitudinal de LS
Propuesta alternativa a la Figure 5: boxplots y observaciones individuales con los mismos contrastes del ANOVA.
7.2 Trayectorias individuales de LS
Trayectorias individuales coloreadas por grupo de LS basal.
7.3 Estadios de fibrosis a lo largo del seguimiento
Distribución de estadios F0-F4 por momento.
7.4 Cambio estandarizado en variables longitudinales
Mapa exploratorio de cambios respecto a basal.
7.5 LS y eventos clínicos durante el seguimiento
Exploración descriptiva por eventos clínicos.
7.6 LS basal frente a marcadores de congestión y laboratorio
Exploración descriptiva de LS basal frente a marcadores seleccionados.
